Development of electrochemical biosensor for breast cancer detection using gold nanoparticle doped CA 15-3 antibody and antigen interaction

International Conference on Signal Processing, Image Processing and Pattern Recognition 2013, ICSIPR 2013

Volumn 1, Issue , 2013, Pages 75-81

  Selwyna, P Georgia Chris ^a   Loganathan, Priyadarshini Ravandhu ^a   Begam, K Haseena ^a  

^a PSG COLLEGE OF TECHNOLOGY   (India)

Author keywords

Biosensor; Breast Cancer detection; CA 15 3; Electrochemical

Indexed keywords

ANTIBODIES; BIOPSY; BIOSENSORS; CHEMICAL DETECTION; COST EFFECTIVENESS; DISEASES; ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY; GOLD NANOPARTICLES; METAL NANOPARTICLES; PATTERN RECOGNITION; SURFACE REACTIONS; VOLTAGE REGULATORS;

BREAST CANCER DETECTION; DETECTABLE SIGNAL; ELECTRICAL CONDUCTIVITY; ELECTROCHEMICAL; ELECTROCHEMICAL BIOSENSOR; ELECTROCHEMICAL IMMUNOSENSORS; SENSITIVE SENSORS; SURGICAL TECHNIQUES;

IMAGE PROCESSING;

EID: 84876780491     PISSN: None     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1109/ICSIPR.2013.6497963     Document Type: Conference Paper

References (24)

1. Parkin DM. Fernandez LM. Use of statistics to assess the global burden of breast cancer. Breast Journal. 12 Suppl I:S70-80, 2006.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005.
3. Greenberg P, Hortobagyi G, Smith T et aL Long-term follow up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197-2205, 1996.
4. Bernard-Marty C. Cardoso F. Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist. 9(6):617-32, 2004.
5. Helena Chang, and Sherry Goldman, Breast Cancer and the Revlon/UCLA Breast Center lecturesummaries.[Online].Available: http://cancerresources. mednet.ucla.edu/5info/5carchive-1ec/2000/5c37revlon.htm.
6. National Breast Cancer Foundation, U.S.A. [Online]. A vailble:http://www.nationalbreastcancer.org/earlydetection/index.html
7. Molina, R.; Auge, J.; Escudero, J.; Marrades, R.; Vinolas, N.; Carcereny, E.; Ramirez, J.; Filella, X. Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumor Biol. 2008, 29, 371-380.
8. Moelans, C.B., de Weger, R.A., Van der Wall, E. and van Diest, P.J. (2011) Current technologies for HER2 testing in breast cancer. Critical Reviews in Oncology/Hemato- logy, Accessed May 5, 2011. doi:l0.l074/mcp.R400001-MCP200
9. Ross, J.S., Fletcher, J.A., Linette, G.P., Stec, J., Clark, E., Ayers, M., et al. (2004) Targeted therapy in breast cancer: The HER-2/neu gene and protein. Molecular & Cellular Proteomics, 3, 379-398. doi:l0.l074/mcp. R400001-MCP200
10. BramweIl, V.H.C., Doig, G.S., Tuck, AB., Wilson, S.M., Tonkin, K.S., Tomiak, A., et al. (2009) Changes over time of extracellular domain of HER2 (ECD/HER2) se-rum levels have prognostic value in metastatic breast cancer. Breast Cancer Research and Treatment, 114, 503-511. doi: 10.1 007/sl 0549-008-0033-2
11. Carney, W.P., Leitzel, K., Ali, S., Neumann, R. and Lip-ton, A (2007) HER-2/neu diagnostics in breast cancer. Breast Cancer Research, 9, 207-217. doi: 10.1 I 86/bcrl 664
12. Jones, S.E. (2008) Metastatic breast cancer: The treat-ment challenge. C/inical Breast Cancer, 8, 224-233. doi: I 0.1 038/nrc276I
13. Mukhopadhyay, P., Chakraborty, S., Ponnusamy, M.P., Lakshmanan, 1., Jain, M. and Batra, S. K. (2011) Mucins in the pathogenesis of breast cancer: Implications in di-agnosis, prognosis and therapy. Biochimica et Biophysica Acta, 1815, 224-240.
14. Kufe, D.W. (2009) Mucins in cancer: Function, prognosis and therapy. Nature Reviews Cancer, 9, 874-885. doi: I 0.1 01 6/j.tibs.2009. I 0.003
15. Senapati, S., Das, S. and Batra, S.K. (2010) Mu-cininteracting proteins: From function to therapeutics. Trends in Biochemical Sciences, 35, 236-245. doi: I 0.1 016/j.tibs.2009.1 0.003
16. Duffy, M.J. (1999) CA 15-3 and related mucins as circulating markers in breast cancer. Annals of C/inical Biochemistry, 36, 579-586.
17. Bafua, S., Kaur, S. and Batra, S.K. (2010) Mem-brane-bound mucins: The mechanistic basis for altera-tions in the growth and survival of cancer cells. Onco-gene, 29, 2893-2904. doi: I 0.1 038/onc.20 I 0.87
18. Lagow, E., DeSouza, M.M. and Carson, D.D. (1999) Mammalian reproductive tract mucins. Human Reproduction, 15, 280-292.
19. Agrawal, B., Gendler, S.J. and Longenecker, B.M. (1998) The biological role of mucins in cellular interactions and immune regulation: Prospects for cancer immunotherapy. Molecular Medicine Today, 4, 397-403. doi:10.1016/SI357- 4310(98)01322-7
20. Brayman, M., Thathiah, A. and Carson, D.D. (2004) MUCl: A multifunctional cell surface component of re-productive tissue epithelia. Reproductive Biology and Endocrinology, 2, 1-9. doi:l0.1186/1477-7827-2-4
21. Parry, S., Silverman, H.S., McDermott, K., WiIIis, A, Hollingsworth, M.A. and Harris, A (2001) Identification of MUCI proteolytic cleavage sites in vivo. Biochemical and Biophysical Research Communications, 283, 715- 720. doi: 10.1 006/bbrc.2001.4775
22. Welsh, J.B., Sapinoso, L.M., Kern, S.G., Brown, D.A, Liu, T., Bauskin, AR., et al. (2003) Large-scale delinea-tion of secreted protein biomarkers overexpressed in cancer tissue and serum. Proceedings ofthe National Academy ofSciences USA, 100, 3410-3415. doi: I 0.1073/pnas.0530278100
23. Duffy, M.J., Duggan, c., Keane, R., Hili, A.D.K., McDermott, E., Crown, J. and O'Higgins, N. (2004) High preoperative CA 15-3 concentrations predict ad-verse outcome in node-negative and node-positive breast cancer: Study of 600 patients with histologically con-firmed breast cancer. Clinical Chemistry, 50, 559-563. doi: 10. I 373/clinchem.2003.025288
24. Tampellini, M., Berruti, A, Gerbino, A, Buniva, T., Tor-ta, M., Gorzegno, G., et al. (1997) Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly di-agnosed metastatic disease. British Journal of Cancer, 75, 698-702. doi: 10.1038/bjc.1997.124